Citius Oncology enters up to $25 million senior secured loan facility with Avenue Capital Group

Citius Pharmaceuticals Inc
Tenx Keane Acquisition

Citius Pharmaceuticals Inc

CTXR

0.00

Tenx Keane Acquisition

CTOR

0.00
  • Citius Oncology entered senior secured term loan credit facility with Avenue Venture Opportunities Fund II, providing up to USD 25 million to support LYMPHIR commercialization.
  • Facility includes USD 10 million initial tranche funded at closing, with up to USD 15 million in additional tranches tied to revenue milestones and liquidity conditions.
  • Avenue received warrants for 11,111,111 shares at USD 0.9 per share, with additional warrant coverage tied to any future tranche funding.
  • Separate warrant exercise agreement with single institutional investor expected to deliver about USD 11.5 million in gross proceeds at USD 0.9 per share, alongside issuance of new unregistered warrants for 25,555,556 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52019) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.